Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Down 51.0% in November

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 38,100 shares, a decrease of 51.0% from the October 31st total of 77,800 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Bio-Path in a research note on Sunday, November 24th. They set a “sell” rating for the company.

Institutional Trading of Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.74% of the company’s stock.

Bio-Path Price Performance

NASDAQ:BPTH remained flat at $0.77 during trading hours on Friday. 21,582 shares of the company were exchanged, compared to its average volume of 1,097,792. The firm’s fifty day moving average is $0.95 and its 200-day moving average is $1.47. Bio-Path has a 12-month low of $0.61 and a 12-month high of $12.37.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.